List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7047290/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mutations in the Genes for Cardiac Troponin T and α-Tropomyosin in Hypertrophic Cardiomyopathy. New England Journal of Medicine, 1995, 332, 1058-1065.	27.0	887
2	Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nature Medicine, 2003, 9, 1477-1483.	30.7	606
3	Cytokine Gene Expression After Myocardial Infarction in Rat Hearts. Circulation, 1998, 98, 149-156.	1.6	407
4	Evidence for a Role of Mast Cells in the Evolution to Congestive Heart Failure. Journal of Experimental Medicine, 2002, 195, 375-381.	8.5	224
5	Anti–Monocyte Chemoattractant Protein-1/Monocyte Chemotactic and Activating Factor Antibody Inhibits Neointimal Hyperplasia in Injured Rat Carotid Arteries. Circulation Research, 1999, 84, 306-314.	4.5	222
6	Enhanced Expression of Hepatocyte Growth Factor/c-Met by Myocardial Ischemia and Reperfusion in a Rat Model. Circulation, 1997, 95, 2552-2558.	1.6	182
7	Dilated Cardiomyopathy Associated With Hepatitis C Virus Infection. Circulation, 1995, 92, 2519-2525.	1.6	167
8	Increased Expression of Interleukin-1β and Monocyte Chemotactic and Activating Factor/Monocyte Chemoattractant Protein-1 in the Hypertrophied and Failing Heart With Pressure Overload. Circulation Research, 1997, 81, 664-671.	4.5	158
9	Cyclic Stretch Upregulates Production of Interleukin-8 and Monocyte Chemotactic and Activating Factor/Monocyte Chemoattractant Protein-1 in Human Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 894-901.	2.4	143
10	Plasma Levels of the Monocyte Chemotactic and Activating Factor/Monocyte Chemoattractant Protein-1 are Elevated in Patients with Acute Myocardial Infarction. Journal of Molecular and Cellular Cardiology, 1997, 29, 419-423.	1.9	140
11	Persistent Expression of Cytokine in the Chronic Stage of Viral Myocarditis in Mice. Circulation, 1996, 94, 2930-2937.	1.6	140
12	Serial circulating concentrations of câ€reactive protein, interleukin (il)â€4, and ilâ€6 in patients with acute left heart decompensation. Clinical Cardiology, 1999, 22, 811-813.	1.8	136
13	Neutralization of interleukin-1β in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. Journal of the American College of Cardiology, 2001, 38, 1546-1553.	2.8	134
14	Treatment of Experimental Viral Myocarditis With Interleukin-10. Circulation, 1999, 100, 1102-1108.	1.6	130
15	Histone Acetyltransferase Activity of p300 Is Required for the Promotion of Left Ventricular Remodeling After Myocardial Infarction in Adult Mice In Vivo. Circulation, 2006, 113, 679-690.	1.6	130
16	Effects of prednisolone on acute viral myocarditis in mice. Journal of the American College of Cardiology, 1986, 7, 868-872.	2.8	124
17	The Global Burden of Myocarditis: Part 1: A Systematic Literature Review for the Global Burden of Diseases, Injuries, and Risk Factors 2010 Study. Global Heart, 2014, 9, 121.	2.3	110
18	Mast Cells Cause Apoptosis of Cardiomyocytes and Proliferation of Other Intramyocardial Cells In Vitro, Circulation, 1999, 100, 1443-1449.	1.6	109

#	Article	IF	CITATIONS
19	Myocarditis and Heart Failure Associated With Hepatitis C Virus Infection. Journal of Cardiac Failure, 2006, 12, 293-298.	1.7	102
20	Hepatitis C Virus from the Hearts of Patients with Myocarditis and Cardiomyopathy. Laboratory Investigation, 2000, 80, 1137-1142.	3.7	100
21	Increased Circulating Hepatocyte Growth Factor in the Early Stage of Acute Myocardial Infarction. Biochemical and Biophysical Research Communications, 1996, 221, 391-395.	2.1	93
22	Hepatitis C Virus Infection and Cardiomyopathies. Circulation Research, 2005, 96, 144-147.	4.5	90
23	Roles and Relationship of Macrophages and Monocyte Chemotactic and Activating Factor/Monocyte Chemoattractant Protein-1 in the Ischemic and Reperfused Rat Heart. Laboratory Investigation, 2000, 80, 1127-1136.	3.7	86
24	FTY720, a New Immunosuppressant, Promotes Long-Term Graft Survival and Inhibits the Progression of Graft Coronary Artery Disease in a Murine Model of Cardiac Transplantation. Circulation, 1999, 100, 1322-1329.	1.6	83
25	Amiodarone Inhibits Production of Tumor Necrosis Factor-α by Human Mononuclear Cells. Circulation, 1997, 96, 1386-1389.	1.6	82
26	Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. Journal of the American College of Cardiology, 1999, 33, 1400-1407.	2.8	81
27	Molecular and Immune Mechanisms in the Pathogenesis of Cardiomyopathy. Japanese Circulation Journal, 1997, 61, 275-291.	1.0	80
28	Modulation of Cytokine Production and Protection Against Lethal Endotoxemia by the Cardiac Glycoside Ouabain. Circulation, 1997, 96, 1501-1506.	1.6	79
29	Epidemiologic and Clinical Characteristics of Cardiomyopathies in Japan. Results From Nationwide Surveys Circulation Journal, 2002, 66, 323-336.	1.6	76
30	Coxsackie virus B3 perimyocarditis in BALB/c mice: Experimental model of chronic perimyocarditis in the right ventricle. Journal of Pathology, 1980, 131, 97-106.	4.5	74
31	Detection of Hepatitis C Virus RNA from the Heart of Patients with Hypertrophic Cardiomyopathy. Biochemical and Biophysical Research Communications, 1996, 222, 678-682.	2.1	74
32	Beneficial Effects of Amlodipine in a Murine Model of Congestive Heart Failure Induced by Viral Myocarditis. Circulation, 1997, 95, 245-251.	1.6	74
33	Hepatitis C virus-associated tubulointerstitial injury. American Journal of Kidney Diseases, 2003, 41, 767-775.	1.9	71
34	High Doses of Digitalis Increase the Myocardial Production of Proinflammatory Cytokines and Worsen Myocardial Injury in Viral Myocarditis. Japanese Circulation Journal, 1999, 63, 934-940.	1.0	68
35	Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. European Journal of Heart Failure, 2003, 5, 669-677.	7.1	66
36	Cytokine Gene Therapy for Myocarditis by In Vivo Electroporation. Human Gene Therapy, 2001, 12, 1289-1297.	2.7	65

#	Article	IF	CITATIONS
37	Prevention of viral myocarditis with recombinant human leukocyte interferon α A/D in a murine model. Journal of the American College of Cardiology, 1987, 9, 1320-1325.	2.8	61
38	Angiotensin II Receptor Antagonist TCV-116 Reduces Graft Coronary Artery Disease and Preserves Graft Status in a Murine Model. Circulation, 1996, 93, 333-339.	1.6	60
39	Hepatitis C Virus Infection and Heart Diseases. Japanese Circulation Journal, 1998, 62, 389-391.	1.0	58
40	Mast Cells Play a Critical Role in the Pathogenesis of Viral Myocarditis. Circulation, 2008, 118, 363-372.	1.6	58
41	Cytokines in myocarditis and cardiomyopathies. Current Opinion in Cardiology, 1996, 11, 302-309.	1.8	57
42	Differential Modulation of Cytokine Production by Drugs: Implications for Therapy in Heart Failure. Journal of Molecular and Cellular Cardiology, 1996, 28, 2491-2499.	1.9	56
43	Characterization of the human nebulette gene: a polymorphism in an actin-binding motif is associated with nonfamilial idiopathic dilated cardiomyopathy. Human Genetics, 2000, 107, 440-451.	3.8	55
44	Antiâ€inflammatory effects of eplerenone on viral myocarditis. European Journal of Heart Failure, 2009, 11, 349-353.	7.1	47
45	Calcium Channel Blockers Differentially Modulate Cytokine Production by Peripheral Blood Mononuclear Cells. Circulation Journal, 2010, 74, 567-571.	1.6	47
46	Gene Expression of Cardiac Mast Cell Chymase and Tryptase in a Murine Model of Heart Failure Caused by Viral Myocarditis. Circulation Journal, 2003, 67, 881-884.	1.6	45
47	Nifedipine inhibits activation of transcription factor NF-κB. Life Sciences, 2000, 67, 2655-2661.	4.3	44
48	Hypertrophic Cardiomyopathy as a Manifestation of Cardiac Sarcoidosis. Japanese Circulation Journal, 2000, 64, 679-683.	1.0	42
49	Contribution of Endothelin-1 to Myocardial Injury in a Murine Model of Myocarditis. Circulation, 1999, 100, 1823-1829.	1.6	40
50	Suppression of cytokines and nitric oxide production, and protection against lethal endotoxemia and viral myocarditis by a new NF-κB inhibitor. European Journal of Heart Failure, 2004, 6, 137-144.	7.1	39
51	Immediate Increase in Circulating Hepatocyte Growth Factor/Scatter Factor by Heparin. Journal of Molecular and Cellular Cardiology, 1998, 30, 2145-2149.	1.9	37
52	Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line. Life Sciences, 1994, 54, PL11-PL16.	4.3	36
53	Left ventricular pressure-volume relationship in a murine model of congestive heart failure due to acute viral myocarditis. Journal of the American College of Cardiology, 2002, 40, 1506-1514.	2.8	36
54	Attenuation of virus-induced myocardial injury by inhibition of the angiotensin II type 1 receptor signal and decreased nuclear factor-kappa B activation in knockout mice. Journal of the American College of Cardiology, 2003, 42, 2000-2006.	2.8	36

#	Article	IF	CITATIONS
55	Protective Role of Interleukin-12 in Viral Myocarditis. Journal of Molecular and Cellular Cardiology, 1997, 29, 2327-2334.	1.9	34
56	Effects of Free Immunoglobulin Light Chains on Viral Myocarditis. Circulation Research, 2010, 106, 1533-1540.	4.5	34
57	Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells. Journal of Molecular and Cellular Cardiology, 1995, 27, 2265-2273.	1.9	33
58	Calcium channel blockers and modulation of innate immunity. Current Opinion in Infectious Diseases, 2011, 24, 254-258.	3.1	32
59	Hepatocyte Growth Factor Is a Major Mediator in Heparin-Induced Angiogenesis. Biochemical and Biophysical Research Communications, 1999, 255, 80-87.	2.1	31
60	Apical Hypertrophic Cardiomyopathy and Hepatitis C Virus Infection. Japanese Circulation Journal, 1999, 63, 433-438.	1.0	30
61	Interferon Treatment for Dilated Cardiomyopathy and Striated Myopathy Associated With Hepatitis C Virus Infection Based on Serial Measurements of Serum Concentrations of Cardiac Troponin T. Japanese Circulation Journal, 2000, 64, 321-324.	1.0	30
62	AMLODIPINE INHIBITS THE PRODUCTION OF CYTOKINES INDUCED BY OUABAIN. Cytokine, 2000, 12, 294-297.	3.2	30
63	Pimobendan inhibits the activation of transcription factor NF-lºB. Life Sciences, 2000, 67, 2513-2519.	4.3	30
64	Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis. Journal of the American College of Cardiology, 2001, 37, 1713-1718.	2.8	30
65	Circulating Hepatocyte Growth Factor as a Diagnostic Marker of Thrombus Formation in Patients With Cerebral Infarction. Circulation Journal, 2002, 66, 216-218.	1.6	30
66	Measurement of Serum Concentrations of Cardiac Troponin T in Patients with Hypereosinophilic Syndrome. A Sensitive Non-invasive Marker of Cardiac Disorder Internal Medicine, 2000, 39, 350.	0.7	28
67	Prognosis and prognostic factors in patients with hypertrophic cardiomyopathy in Japan: results from a nationwide study. Heart, 2007, 93, 711-715.	2.9	28
68	The role of inflammatory mediators in the failing heart: immunomodulation of cytokines in experimental models of heart failure. , 2001, 6, 129-136.		25
69	Comparative study of201Tl-scintigraphic image and myocardial pathologic findings in patients with dilated cardiomyopathy. Annals of Nuclear Medicine, 1996, 10, 307-314.	2.2	24
70	Hepatitis C Virus Infection and Hypertrophic Cardiomyopathy. Annals of Internal Medicine, 1998, 129, 749.	3.9	24
71	Mural thrombus in experimental viral myocarditis in mice: relation between thrombosis and congestive heart failure. Cardiovascular Research, 1986, 20, 665-671.	3.8	23
72	Denopamine, a β1-adrenergic agonist, prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: suppression of tumor necrosis factor-α production in the heart. Journal of the American College of Cardiology, 1998, 32, 808-815.	2.8	23

#	Article	IF	CITATIONS
73	AMIODARONE INHIBITS INTERLEUKIN 6 PRODUCTION AND ATTENUATES MYOCARDIAL INJURY INDUCED BY VIRAL MYOCARDITIS IN MICE. Cytokine, 2002, 17, 197-202.	3.2	23
74	Anti-inflammatory therapy for heart failure. Current Opinion in Pharmacology, 2004, 4, 171-176.	3.5	23
75	Encephalomyocarditis virus myocarditis in inbred strains of mice. Chronic stage Japanese Circulation Journal, 1982, 46, 1192-1196.	1.0	22
76	The use of cytokine inhibitors. International Journal of Cardiology, 1997, 62, S3-S12.	1.7	22
77	Hepatocyte Growth Factor and Cardiovascular Thrombosis in Patients Admitted to the Intensive Care Unit. Circulation Journal, 2004, 68, 645-649.	1.6	22
78	Prognosis and Prognostic Factors in Patients With Idiopathic Dilated Cardiomyopathy in Japan Results From a Nationwide Study. Circulation Journal, 2008, 72, 343-348.	1.6	22
79	Role of Cytokines in Autoimmune Myocarditis and Cardiomyopathy. Autoimmunity, 2001, 34, 165-168.	2.6	21
80	Thrombosis Increases Circulatory Hepatocyte Growth Factor by Degranulation of Mast Cells. Circulation, 2002, 106, 3133-3138.	1.6	21
81	Circulating Hepatocyte Growth Factor as an Early Marker of Arterial Thrombus Formation. Japanese Circulation Journal, 1998, 62, 311-313.	1.0	20
82	Calcium channel blocker-induced protection against cardiovascular damage. International Journal of Cardiology, 1997, 62, S39-S46.	1.7	19
83	Inhibitory effects of Pycnogenol® on hepatitis C virus replication. Antiviral Research, 2015, 113, 93-102.	4.1	19
84	Autoantibodies Against Vimentin in a Murine Model of Myocarditis. Autoimmunity, 1994, 18, 145-148.	2.6	18
85	Inotropic agents differentially inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages. Life Sciences, 1996, 59, PL121-PL125.	4.3	18
86	Hepatitis C Virus and Cardiomyopathy. Herz, 2000, 25, 249-254.	1.1	18
87	French Maritime Pine Bark Extract Inhibits Viral Replication and Prevents Development of Viral Myocarditis. Journal of Cardiac Failure, 2007, 13, 785-791.	1.7	17
88	Vesnarinone prolongs survival and reduces lethality in a murine model of lethal endotoxemia. Life Sciences, 1994, 55, 1735-1741.	4.3	16
89	Serial evaluation of fatty acid metabolism in rats with myocardial infarction by pinhole SPECT. Journal of Nuclear Cardiology, 2001, 8, 472-481.	2.1	16
90	Myocardial involvement in coronavirus disease 19. Herz, 2020, 45, 719-725.	1.1	15

#	Article	IF	CITATIONS
91	Pathogenesis and preventive and therapeutic trials in an animal model of dilated cardiomyopathy induced by a virus Japanese Circulation Journal, 1987, 51, 661-664.	1.0	14
92	Heparin accelerates liver regeneration following portal branch ligation in normal and cirrhotic rats with increased plasma hepatocyte growth factor levels. Journal of Hepatology, 2002, 37, 87-92.	3.7	14
93	Treatment Options in Myocarditis. Herz, 2007, 32, 452-456.	1.1	14
94	Gelsolin and Cardiac Myocyte Apoptosis. Circulation Research, 2009, 104, 829-831.	4.5	14
95	Immunoglobulin free light chains: an inflammatory biomarker of diabetes. Inflammation Research, 2020, 69, 715-718.	4.0	14
96	Cytokine Gene Expression During the Development of Graft Coronary Artery Disease in Mice. Japanese Circulation Journal, 1999, 63, 775-782.	1.0	12
97	Hepatitis C Virus and Cardiomyopathy. Internal Medicine, 2001, 40, 78-79.	0.7	12
98	Nifedipine inhibits the activation of inflammatory and immune reactions in viral myocarditis. Life Sciences, 2009, 85, 235-240.	4.3	12
99	Clinical Practice of Hepatitis: Myocardial Diseases, Nephritis, and Vasculitis Associated with Hepatitis Virus Internal Medicine, 2001, 40, 182-184.	0.7	11
100	REDUCED HIGH SERUM HEPATOCYTE GROWTH FACTOR LEVELS AFTER SUCCESSFUL CARDIOVERSION IN PATIENTS WITH ATRIAL FIBRILLATION. Clinical and Experimental Pharmacology and Physiology, 2004, 31, 145-151.	1.9	11
101	Endothelin Antagonism with Bosentan: Current Status and Future Perspectives. Cardiovascular Drug Reviews, 2002, 20, 1-18.	4.1	11
102	Immunoglobulin free light chains as an inflammatory biomarker of heart failure with myocarditis. Clinical Immunology, 2020, 217, 108455.	3.2	11
103	Right ventricular aneurysms complicating encephalomyocarditis virus myocarditis in mice Japanese Circulation Journal, 1983, 47, 1322-1324.	1.0	10
104	Circulating Hepatocyte Growth Factor as a Marker of Thrombus Formation in Unstable Angina Pectoris. Japanese Circulation Journal, 2000, 64, 805-807.	1.0	10
105	Roles of Hepatocyte Growth Factor and Mast Cells in Thrombosis and Angiogenesis. Cardiovascular Drugs and Therapy, 2004, 18, 321-326.	2.6	10
106	Diagnosis and treatment of HCV heart diseases. Expert Review of Cardiovascular Therapy, 2021, 19, 493-499.	1.5	10
107	Encephalomyocarditis (EMC) virus myocarditis in DBA/2 mice. I. Acute stage Japanese Circulation Journal, 1981, 45, 1403-1408.	1.0	9
108	Successive infection of coxsackievirus B3 and encephalomyocarditis virus: An animal model of chronic myocarditis. Journal of Pathology, 1992, 167, 341-347.	4.5	9

#	Article	IF	CITATIONS
109	Leukocytes are the major target of hepatitis C virus infection: Possible mechanism of multiorgan involvement including the heart. CVD Prevention and Control, 2010, 5, 51.	0.7	9
110	Immunoglobulin Free Light Chains as Inflammatory Biomarkers of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e009017.	4.8	9
111	Effects of pranidipine, a calcium channel antagonist, in an avian model of heart failure. Cardiovascular Drugs and Therapy, 1999, 13, 455-463.	2.6	8
112	Global alert and response network for hepatitis C virus-derived heart diseases: A call to action. CVD Prevention and Control, 2009, 4, 109.	0.7	8
113	Novel Biomarkers of Inflammation for the Management of Diabetes: Immunoglobulin-Free Light Chains. Biomedicines, 2022, 10, 666.	3.2	8
114	Role of Cytokines in the Syndrome of Heart Failure Internal Medicine, 1996, 35, 60-63.	0.7	6
115	Role of substance P in viral myocarditis in mice. Heart and Vessels, 2010, 25, 348-352.	1.2	5
116	Protective effects of Mu-Fang-Ji-Tang against myocardial injury in a murine model of congestive heart failure induced by viral myocarditis. Life Sciences, 1998, 62, 1139-1146.	4.3	4
117	Genes of the Major Histocompability Complex Class II Influence the Phenotype of Cardiomyopathies Associated With Hepatitis C Virus Infection. Developments in Cardiovascular Medicine, 2003, , 515-521.	0.1	4
118	Cardiomyopathies and Heart Failure. Developments in Cardiovascular Medicine, 2003, , 1-15.	0.1	3
119	Elevated circulating levels of tumor necrosis factor in patients with mitral valve disease and ventricular septum defect. Heart and Vessels, 1996, 11, 218-220.	1.2	2
120	Hepatitis Cvirus and Cardiomyopathy. Developments in Cardiovascular Medicine, 2003, , 325-339.	0.1	2
121	Transition from Compensated to Decompensated Cardiac Hypertrophy. Heart Failure Reviews, 1999, 4, 379-388.	3.9	1
122	Emerging treatments for viral myocarditis. Future Cardiology, 2005, 1, 683-692.	1.2	1
123	Myocarditis and Pericarditis. , 2021, , .		1
124	Immunoglobulin Free Light Chains: A Biomarker of Diabetes. SSRN Electronic Journal, 0, , .	0.4	1
125	Immunomodulatory therapy and survival with cardiac disease. Heart Failure Reviews, 1996, 1, 221-227.	3.9	0
126	A Patient With Hypertrophic Cardiomyopathy Accompanied by Right Ventricular Dilation of Unknown Cause. Japanese Circulation Journal, 1999, 63, 137-140.	1.0	0

#	Article	IF	CITATIONS
127	Commentary. Evidence-based Cardiovascular Medicine, 2005, 9, 269-270.	0.0	0
128	Cytokines and Heart Failure: Pathophysiological Roles and Therapeutic Implications. , 2000, , 35-45.		0
129	Immunomodulation of Cytokines in Experimental Models of Heart Failure. Developments in Cardiovascular Medicine, 2001, , 69-76.	0.1	0